Clinuvel Pharmaceuticals Limited

Recording in progress.

Hello, everyone. Thank you for joining Clinuvel's investor webinar. I'm Stella of Monsoon Communications. In today's webinar, Clinuvel will share their healthier results and operational highlights for the six months ended on 31st December 2025. I will now hand over to Malcolm Bull, Head of the Australian Operations and Investor Relations to conduct the proceedings.

Thank you, Stella, for the introduction. I'd first like to welcome members of Clinuvel management team to the webinar. Not surprisingly, reflecting the focus of the webinar on the financial results for the half year to December 25, we have Chief Financial Officer Peter Vaughan. We are joined by two executives who are leading the business in key operational areas Director of Clinical Affairs Dr Emily Rottenberger and Director of North American Operations Dr Linda Teng We're also joined by our Managing Director Philippe Walden I'd like to acknowledge there are several analysts on the line who cover Clinuvel and will ask some questions in the webinar It would be remiss of me if I didn't say on behalf of management and the board that we appreciate your work on Clinuvel. Your role in telling our story to a wider audience than we could reach ourselves and your involvement in this webinar. It's pleasing also that there are over 175 participants to the webinar reflecting increasing interest in Clinuvel. So welcome one and all. Before going further, I think it's appropriate to highlight why we have five executives in today's webinar. So you frequently see Philippe, our Chief Operations Officer Lachlan Hay, Peter Vaughan and Investor Relations presenting the company to a range of stakeholders. We have received feedback that it would be good to have greater access and the opportunity to hear from other executives. So for today's webinar, noting this is not the forum for a strategic review, but as a courtesy to you all, we include Dr. Roddenberger and Dr. Teng to answer questions and provide their insights direct to you. Today's webinar will be in two parts. First, a discussion of the half-year results, and second, the analysts online will be called upon to ask questions of the CFO and management. We will be talking today about plans and intended outcomes. So draw your attention to the forward-looking statement or safe harbour statement on screen that identifies a range of risks that can materialise and impact their achievement. So I think 10 seconds to review that is enough and that is on our website and on all of our announcements. I now kindly invite the CFO to summarise the results. Peter.